This week in Matty Ice’s blog we will be researching something called a monoclonal antibody, specifically the drug called Belimumab.
First off we need to explain what a monoclonal antibody is. A monoclonal antibody is a synthetically produced antibody to specifically target certain diseases. This is done by transferring human genes into animals and the scientists introduce antigens to these animals to produce the desired human antibodies. These antibodies are then transferred to a human by injection, which provide protection against autoimmune disorders in which patients own B cells are attacking their tissues.
The monoclonal antibody therapy, Belimumab, specifically targets Systemic Lupus Erythematosus (SLE). SLE is an autoimmune disorder, the body causes it self harm by attacking tissues and causing inflammation. The purpose of this drug is to block the production of B cells, in order to protect the body from further harm because the B cells are produced and are attacking the body. This is done by blocking the action of B cell stimulator proteins, which is responsible for the production of B cells.
The side effects to the this drug are relatively adverse. Side affects include nausea, diarrhea, vomiting, stomach pain, fever, stuffy or runny nose, bronchitis, insomnia, pain in extremities, migraine, and sore throat. Other side affects include allergic reactions, swelling of lips, face, tongue, mouth, and throat, difficulty breathing, low blood pressure, dizziness, fainting, rash, redness or swelling of skin. Belimumab, reduces the activity of the immune system making the body more susceptible to infections, heart problems, and certain cancers.
Belimumab negatively affects the innate response of the immune system. This is because B cell production is affected by this drug. B cell are produced for humoral immunity by the body, and this drug stops that making the body more susceptible to various diseases and ailments.
Matty Ice signing off! Peace!
Matthew Smith's Blog 